Accordingly, anti-cytokine aAbs (e.g., antibodies against IFN-α, IFN-ε, IL-6, IL-22, GM-CSF, and TNF-α) were proposed for COVID-19 and non-COVID-19 treatment, although with different results, since some improved clinical outcomes, while others had no benefit [190]. The gene discussed is IL22; the disease is COVID-19.